Loading…
Nuvisan
GLP-certifiedAccepting studiesThe Science CRO
About
Nuvisan is a German CRO/CDMO describing itself as "the unique CRO/CDMO with extensive pharma experience and industry-leading scientific expertise, providing highest-quality end-to-end solutions" from drug discovery through commercialisation. Its service lines are Discovery (omics and biomarkers, biosciences, compound screening, pharmacology, chemistry, discovery DMPK), Preclinical (development DMPK, preclinical safety/toxicology, bioanalysis), Clinical (phase 1 and 2 services, bioanalysis, biomarkers, clinical trial supply), CMC (drug substances, drug products, pharmaceutical analytical services, regulatory) and Digital. The company states its preclinical safety toxicology work is performed in a GLP-certified test facility and covers human and veterinary pharmaceuticals, industrial products and agrochemicals.
Strategic positioning
Integrated discovery-to-Phase-II CRO spanning DMPK, safety, bioanalysis & CMC.
Deterministic scores · rules-based, not AIiHow these scores are obtained: each one is computed from this profile's listed attributes — capability checkboxes, certifications, capacity figures and coverage — by a fixed formula, recomputed on every page load. Deterministic and rules-based means the score comes from a fixed, transparent formula over listed attributes — the same inputs always produce the same score. It is not AI: there is no model, no learning, and no hidden weighting. Whether a score is relevant to you depends on your specific project: a capability that raises the number may not matter for your work, and a niche strength your project needs may barely move it. Capability scores are a directional starting point, not a verdict. A lower score does not disqualify a company or consultant, and no decision should rest on the score alone — always contact the company directly to confirm the specifics for your project.
Advanced-therapy focus iAdds 25 points if the profile flags advanced-therapy focus, plus 8 points per advanced modality listed (biologics, cell and gene therapy, mRNA/LNP, vaccines, radiopharma, sterile injectables, ATMPs, ADCs, biosimilars) capped at 45, plus 8 points per advanced therapeutic area (oncology, rare disease, immunology, infectious disease, vaccines) capped at 30. Levels: 75+ ATMP / advanced-therapy specialist | 50-74 Advanced-therapy active | 25-49 Selective | below 25 General preclinical. Whether this dimension matters for you depends on your specific project.
8General preclinical
GLP readiness iBlends GLP status (GLP + GCLP 32, OECD GLP or FDA GLP 28, non-GLP 0, plus 5 if GLP certified), 15 for AAALAC accreditation, data-integrity level (ALCOA+ validated 20, Established 12, Basic 4), 8 for Part 11 systems, and a quarter of the self-reported audit-readiness score capped at 25. Levels: 85+ Inspection-ready GLP | 65-84 GLP-established | 45-64 GLP-capable | below 45 Discovery / non-GLP. Whether this dimension matters for you depends on your specific project.
20Discovery / non-GLP
Study breadth iCounts the study capabilities this lab lists: 8 points per distinct capability category capped at 40, plus 2.5 points per capability capped at 35, plus up to 25 points scaled by the share of capabilities offered under GLP. Scores 0 (No capabilities listed) when no capabilities are entered. Levels: 80+ Comprehensive GLP services | 60-79 Broad capabilities | 40-59 Focused | below 40 Specialized. Whether this dimension matters for you depends on your specific project.
0No capabilities listed
Regulatory standing iAdds 6 points per regulatory agency supported capped at 30, a quarter of the CAPA effectiveness percentage capped at 25, up to 25 points scaled by the share of listed inspections with a clean (no-action) outcome (12 if none listed), and a findings-control term starting at 20 and losing 2 points per open finding or inspection finding. Levels: 80+ Multi-region, inspection-clean | 60-79 Strong regulatory standing | 40-59 Established | below 40 Developing. Whether this dimension matters for you depends on your specific project.
32Developing
Animal-model depth iBuilt from the animal models listed: 6 points per distinct species capped at 30, 6 per distinct model category capped at 25, 2 per model capped at 20, up to 15 scaled by the share marked regulatory-accepted, and 3 per advanced model (humanized, xenograft, transgenic, disease, knockout, syngeneic) capped at 10. Scores 0 (No models listed) when none are entered. Levels: 80+ Extensive model portfolio | 60-79 Broad models | 40-59 Established | below 40 Core models. Whether this dimension matters for you depends on your specific project.
0No models listed
Capacity iCombines housing scale (10 points per power of ten of animal capacity, capped at 30), 1.5 points per study room capped at 20, 2 points per country covered capped at 20, 15 if currently accepting studies, and turnaround speed (23 minus the quoted weeks, kept between 0 and 15; 7 when turnaround is not reported). Levels: 75+ High availability | 55-74 Good capacity | 35-54 Moderate | below 35 Constrained. Whether this dimension matters for you depends on your specific project.
22Constrained
Core scientific expertise
DMPKPreclinical safetyBioanalysisMedicinal chemistryBiomarkers
Therapeutic areas
OncologyDermatology
NUV
Nuvisan
Preclinical / GLP · Germany
Live record · illustrative seed data · scores deterministic, rules-based — not AI · regulatory signals are educational, not a compliance determination.